FLT3 inhibitor · small molecule
crenolanib
0 active trials, targeting FLT3. Not approved for any biomarker on marked.bio yet.
Also known as CP-868596, crenolanib besylate.
Counts only trials that select patients by one of the biomarkers on marked.bio, not every trial of this drug.
Biomarkers
| Biomarker | Active trials | All trials | Furthest active phase |
|---|---|---|---|
| FLT3 mutation (ITD/TKD) | 0 | 10 | – |
Trials
0 of 10 trials shown
-
Study of Crenolanib vs Midostaurin Following Induction Chemotherapy and Consolidation Therapy in Newly Diagnosed FLT3 Mutated AML
crenolanibmidostaurin FDA EUcytarabineDuanorubicin
Presence of FLT3-ITD and/or D835 mutation(s) in bone marrow or peripheral blood
FLT3 mutation (ITD/TKD)Newly Diagnosed FLT3 Mutated AML
-
Study Investigating the Efficacy of Crenolanib With Chemotherapy vs Chemotherapy Alone in R/R FLT3 Mutated AML
crenolanibcytarabinemitoxantronefludarabineidarubicinpegfilgrastim
Presence of FLT3-ITD and/or D835 mutation(s)
FLT3 mutation (ITD/TKD)Relapsed/Refractory Acute Myeloid Leukemia With FLT3 Activating Mutations
-
Study of Crenolanib in Combination With Chemotherapy in Patients With Relapsed or Refractory Acute Myeloid Leukemia and Activating FLT3 Mutations
mitoxantronecytarabinecrenolanib
positivity of FLT3-ITD and FLT3-TKD is defined based on genescan analysis with a mutant to wild-type ratio equal…
FLT3 mutation (ITD/TKD)Acute Myeloid Leukemia
-
A Study of Crenolanib With Fludarabine and Cytarabine in Pediatric Patients With Relapsed/Refractory FLT3-Mutated Acute Myeloid Leukemia
crenolanibfludarabinecytarabine
Definitive evidence of a FLT3-ITD and/or FLT3-TKD (D835/I836) mutation at the time of enrollment
FLT3 mutation (ITD/TKD)Relapsed/Refractory FLT3-mutated AML
-
Study of Crenolanib Combined With Chemotherapy in FLT3-mutated Acute Myeloid Leukemia Patients
crenolanibidarubicincytarabineazacitidinemitoxantroneetoposidefludarabinepegfilgrastim
FLT3 mutation positive (ITD, TKD or other)
FLT3 mutation (ITD/TKD)Acute Myeloid Leukemia
-
Crenolanib Maintenance Following Allogeneic Stem Cell Transplantation in FLT3-positive Acute Myeloid Leukemia Patients
FLT3-ITD or FLT3-D835 positive disease at any time during disease course.
FLT3 mutation (ITD/TKD)Acute Myeloid Leukemia
-
A Safety and Tolerability Study of Crenolanib in Combination With Chemotherapy in Newly Diagnosed Acute Myeloid Leukemia Patients With FLT3 Mutations
crenolanibcytarabinedaunorubicinidarubicin
Subjects must have tested positive for FLT3-ITD and/or other FLT3 activating mutations
FLT3 mutation (ITD/TKD)Newly Diagnosed AML With FLT3 Activating Mutations
-
Phase II Study of Crenolanib in Subjects With Relapsed/Refractory AML With FLT3 Activating Mutations
Patients must have tested positive for FLT3-ITD and /or other FLT3 activating mutations within \< 60 days of the screening period.
FLT3 mutation (ITD/TKD)Relapsed or Refractory Acute Myeloid Leukemia With FLT3 Activating Mutations
-
A Phase II Study of Crenolanib in Relapsed/Refractory Acute Myeloid Leukemia Patients With FLT3 Activating Mutations
Patients must have tested positive for FLT3-ITD and /or other FLT3 activating mutations within 30 day screening period
FLT3 mutation (ITD/TKD)Acute Myeloid Leukemia With FLT3 Activating Mutations That Has Relapsed or Been Refractory After One or More Prior Therapies
-
Crenolanib in Combination With Sorafenib in Patients With Refractory or Relapsed Hematologic Malignancies
crenolanibsorafenibmethotrexatecytarabineleucovorin
…nt has a relapsed or refractory hematologic malignancy (with any measurable disease) with FLT3-ITD or TKD mutations and one of the following diagnoses:
FLT3 mutation (ITD/TKD)Acute Myeloid Leukemia
No trials match these filters.